Skip to main content

Advertisement

Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib

Fig. 5

In vivo pharmacokinetics and tumor uptake of NPs. a Free C6 was rapidly cleared in the circulatory system, but C6-NPs and LFC-C6-NPs prolonged the circulation time of C6 in vivo. Data are expressed as the mean ± SD (n = 4). b LFC-C6-NPs exhibited much greater C6 delivery in tumor tissues than free C6 and C6-NPs. Data are expressed as the mean ± SD (n = 4). *P < 0.05, **P < 0.01, ***P < 0.001. c Following administration of free C6, C6-NPs and LFC-C6-NPs, the uptake and distribution of C6 (green) in tumor tissues was observed by confocal microscopy. The cell nuclei were counterstained with DAPI (blue)

Back to article page